GlassScriptPhysician profile
Kristen Blake Mitchell
NPI 1912394917
$2,496.76
in general payments reported to CMS, 2019-2025
22 companies · $396 in 2025
The $396 reported for 2025 was more than what 75% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $39.88 · 2020: $54.65 · 2021: $650 · 2022: $544 · 2023: $514 · 2024: $299 · 2025: $396.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,208.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,208.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $559.75 | 2020-2023 | Da Vinci Surgical System |
| Abbvie INC. | $438.95 | 2019-2023 | |
| Femselect INC. | $270.62 | 2023-2024 | Enplace |
| Astellas Pharma US INC | $268.05 | 2021-2025 | Veozah |
| Amgen INC. | $240.54 | 2021-2025 | Evenity, Prolia, Prolia |
| Bayer Healthcare Pharmaceuticals INC. | $69.65 | 2022-2023 | |
| Evofem Biosciences, INC. | $68.74 | 2021-2022 | |
| Mayne Pharma Commercial LLC | $64.83 | 2021-2025 | |
| Novo Nordisk INC | $64.08 | 2022-2025 | Wegovy |
| Organon LLC | $60.85 | 2022-2025 | Nexplanon |
| Exeltis, USA INC. | $56.98 | 2021-2023 | Slynd, Nuvessa |
| Molnlycke Health Care US, LLC | $55.37 | 2023-2025 | Mepilex Border Post-Op Ag, Mepiform |
| Sumitomo Pharma America, INC. | $53.81 | 2023-2025 | Myfembree, Gemtesa |
| Biogen, INC. | $44.71 | 2025 | Zurzuvae |
| Minerva Surgical, INC | $44.27 | 2019-2023 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hologic Sales and Service, LLC | $32.43 | 2020-2025 | Fluent Fluid Management System |
| Shield Therapeutics INC | $22.87 | 2025 | |
| Lilly USA, LLC | $20.18 | 2024 | Zepbound |
| Boston Scientific Corporation | $19.17 | 2025 | Bulkamid |
| Merck Sharp & Dohme LLC | $15.27 | 2021 | |
| Currax Pharmaceuticals LLC | $13.50 | 2025 | Contrave |
| Therapeuticsmd, INC. | $12.14 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kristen Mitchell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.